Characteristics | Control | HIV/HCV co-infection | HIV-infected patients with hypertriglyceridemia | p value |
---|---|---|---|---|
Age (yr) | 42.0 ± 4.3 | 42.7 ± 6.1 | 42.9 ± 9.3 | 0.873 |
Male (%) | 14 (46.7%) | 47 (68.1%) | 109 (66.9%) | 0.104 |
Female (%) | 16 (53.3%) | 22 (31.9%) | 54 (33.1%) | |
Transmission route | ||||
Former plasma donators | -- | 14 (20.3%) | 41 (25.2%) | -- |
Blood transfusion | -- | 39 (59.5%) | 9 (5.5%) | -- |
Intravenous drug users | -- | 7 (7.2%) | 20 (12.3%) | -- |
Sexual transmission | -- | 9 (13.0%) | 89 (54.6%) | -- |
Unknown reason | -- | 0 (0.0%) | 4 (2.5%) | -- |
Biochemistry tests | ||||
ALT (U/L) | 18.7 ± 10.9 | 44.3 ± 40.3 | 32.5 ± 29.3 | 0.001 |
T-BIL (umol/L) | 11.1 ± 3.9 | 12.7 ± 9.2 | 11.4 ± 6.2 | 0.129 |
BUN (mmol/L) | 4.7 ± 1.1 | 4.8 ± 3.9 | 4.9 ± 1.4 | 0.836 |
FPG (mmol/L) | 5.5 ± 1.0 | 5.7 ± 1.7 | 5.7 ± 1.8 | 0.755 |
Blood lipid levels | ||||
TG (mmol/L) | 1.9 ± 1.7 | 1.8 ± 1.1 | 5.7 ± 5.2 | <0.001 |
TC (mmol/L) | 4.9 ± 0.9 | 3.7 ± 1.1 | 5.5 ± 1.7 | <0.001 |
LDL (mmol/L) | 2.8 ± 0.7 | 2.2 ± 0.9 | 2.8 ± 1.0 | <0.001 |
HDL (mmol/L) | 1.4 ± 0.7 | 0.9 ± 0.4 | 1.2 ± 0.3 | <0.001 |
TG ≥2.26 mmol/L (%) | 4 (13.3%) | 12 (17.4%) | 163 (100%) | <0.001 |
1.70 ≤ TG ≤ 2.25 mmol/L | 6 (20.0%) | 11 (15.9%) | 0 (0%) | |
TC ≥6.22 mmol/L | 2 (6.7%) | 2 (2.9%) | 45 (27.6%) | <0.001 |
5.18 ≤ TC ≤ 6.19 mmol/L | 10 (33.3%) | 2 (2.9%) | 39 (23.9%) | |
LDL ≥4.14 mmol/L | 0 (0.0%) | 2 (2.9%) | 14 (8.6%) | 0.041 |
3.37 ≤ LDL ≤ 4.14 mmol/L | 7 (23.3%) | 5 (7.2%) | 24 (14.7%) | |
HDL ≤ 1.04 mmol/L | 7 (23.3%) | 50 (72.4%) | 34 (20.9%) | <0.001 |
Metabolic sydrome | 5 (16.7%) | 13 (18.9%) | 78 (47.9%) | <0.001 |
Liver steatosis | 5 (16.7%) | 14 (20.3%) | 75 (46%) | <0.001 |